These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Lv B; Xu B; Feng Y; Peng K; Xu G; Du J; Zhang L; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y Bioorg Med Chem Lett; 2009 Dec; 19(24):6877-81. PubMed ID: 19896374 [TBL] [Abstract][Full Text] [Related]
6. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635 [TBL] [Abstract][Full Text] [Related]
7. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents. Ding Y; Mao L; Xu D; Xie H; Yang L; Xu H; Geng W; Gao Y; Xia C; Zhang X; Meng Q; Wu D; Zhao J; Hu W Bioorg Med Chem Lett; 2015 Jul; 25(14):2744-8. PubMed ID: 26026363 [TBL] [Abstract][Full Text] [Related]
8. C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors. Koga Y; Sakamaki S; Hongu M; Kawanishi E; Sakamoto T; Yamamoto Y; Kimata H; Nakayama K; Kuriyama C; Matsushita Y; Ueta K; Tsuda-Tsukimoto M; Nomura S Bioorg Med Chem; 2013 Sep; 21(17):5561-72. PubMed ID: 23809172 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543. Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors. Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Wu SH; Huang CY; Huang YL; Wang MH; Liu YW; Tsai CH; Kumar CR; Lee JC Eur J Med Chem; 2012 Sep; 55():32-8. PubMed ID: 22818040 [TBL] [Abstract][Full Text] [Related]
19. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. Washburn WN J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175 [No Abstract] [Full Text] [Related]
20. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents. Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]